Last updated 2026-07-26
- Raised $890k Seed round led by Peregrine Ventures, Jan 2023
Total raised
$890K
Last: Undisclosed Round 2023-02
Stage
Seed
Founded
2022
Headcount
2
HQ
Or Yehuda, Israel
Sector
Health Tech & Life Sciences
About
OncoRedox has developed an innovative platform for the early detection of colorectal cancer using a simple blood sample. The system is based on an AI-powered disposable electrochemical sensor that generates a metabolic fingerprint of the reduction-oxidation (redox) state, enabling highly accurate disease detection through plasma samples. The company has also conducted proof-of-concept studies for detection of other cancers, such as lung and bladder, as well as at-home monitoring of chronic diseases such as Inflammatory Bowel Disease through blood and urine samples.
Funding history · 1 round · $890K total
2023-01
Seed
$890K
★ Peregrine Ventures
Headcount over time
From 3 (2024-03) to 2 (2025-04) · -1 (-33%) · 4 points · source: Finder history + radar grounding
Q&A
- What is OncoRedox's primary focus?
- OncoRedox develops an AI-powered disposable electrochemical sensor for early cancer detection through blood and urine samples, with an initial focus on colorectal cancer.
- When was OncoRedox founded?
- OncoRedox was founded in August 2022.
- How much funding has OncoRedox raised to date?
- OncoRedox has raised a total of $890,000 USD.
- When did OncoRedox complete its Seed funding round and who were the lead investors?
- OncoRedox completed a Seed funding round in February 2023, with lead investors including Peregrine Venture/Incentive Incubator.
- What is OncoRedox's current employee count?
- OncoRedox has 2 employees, falling within the 1-10 employee bucket.
- Who are the founders of OncoRedox and what are their roles?
- The founders of OncoRedox are Prof. Gal Markel, who serves as CMO, and Prof. Hadar Ben-Yoav, who serves as CTO.
- What technologies does OncoRedox utilize in its solutions?
- OncoRedox utilizes Artificial Intelligence and Biologicals in its technology.
- What is the primary sector OncoRedox operates in?
- OncoRedox operates primarily in the Health Tech & Life Sciences sector.
Team · 2
Prof. Gal Markel
Founder · CMO
Prof. Hadar Ben-Yoav
Founder · CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Artificial IntelligenceBiologicals
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
cancer-diagnosticsdiagnosticsmedical-devices
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | oncoredox.com/ |
|---|---|
| linkedin.com/company/90860822 |
Identifiers & details
| Legal name | ONCOREDOX LTD |
|---|---|
| Founded | 2022-8 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | oncoredox.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516656998 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-08-01 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | נתניהו יהונתן 6 אור יהודה |